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Seminarsare older than 50 and comorbidities become more common with age. Anticoagulation has to be
discussed when an ITP patient develops atrial fibrillation, venous or arterial thromboembolism,
myocardial infarction, or stroke. At the same time low platelet counts often prohibit
therapeutic anticoagulation. Guidelines do not give guidance for these situations. This article
summarizes experiences from case reports and small series and suggests an approach to ITP
patients with thrombocytopenia and an indication for anticoagulation.
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mmune thrombocytopenia (ITP) is a rare disor-
der with a yearly incidence rate between 2–
4:100,000 adults. The prevalence has been
estimated at 20:100,000.1–5 ITP affects both old
and young patients with a median age of 50
years.1,3
Older ITP patients are more likely to develop
comorbidities. The incidence of atrial fibrillation
(AFib), coronary artery disease (CAD) with acute
myocardial infarction (AMI), cerebrovascular disease
(CVD) with stroke and transient ischemic attacks
(TIAs), and of venous thromboembolism (VTE)
increases with age. The incidence of AFib in the
non-ITP population is estimated at 1%, and in
those460 years even at 6%.6,7 The prevalence of
stroke is 2%–3% and of CAD 6%.7–9 From age 30 to
75, the risk of VTE increases steadily and exponen-
tially by a factor of 10.10 Anticoagulation poses
a clinical challenge in ITP patients because it is
usually contraindicated with thrombocytopeniablished by Elsevier Inc.
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Open access under CC BY-NC-ND license.o50,000–75,000/mL.11 ITP patients requiring anti-
coagulation have been excluded from all pivotal
studies on newer therapeutic agents and clinical
data are scarce.12,13 This article summarizes experi-
ences from case reports and small series and sug-
gests an approach to the ITP patient with
thrombocytopenia.
ITP AND THROMBOEMBOLIC
COMORBIDITIES
Thrombocytopenia does not protect ITP patients
against thromboembolic disease. Myocardial infarc-
tion, stroke, and VTE occur in ITP patients as they
occur in the normal population14–17 and even with
platelet countso30,000/mL.17,18 One study even
found the risk of VTE in ITP to be as high as in
cancer patients.19 The risk of AFib, AMI, and stroke
might even be higher in ITP patients than in age-
matched controls.20 Another study describes a tran-
sient ischemia-like syndrome in ITP with recurring
dizzy spells, memory loss, and cognitive impairment
progressing to dementia. This syndrome is more
common after splenectomy.21
The pathophysiology of venous and arterial throm-
boembolic events in ITP remains elusive. Paradoxically,
the risk seems to be higher with lower platelet counts.15
This suggests a causal relationship. Hyperreactive young
platelets22 and antiphospholipid antibodies have been
discussed. Hospitalization and immobilization for bleed-
ings and side effects of ITP treatments pose additional
risks. Intravenous immunoglobulin (IVIg)23 and cortico-
steroids (eg, dexamethasone, tranexamic acid)24–26 are
documented prothrombogenic agents. Splenectomyp S83–S88 S83
A. Matzdorff and J.-H. BeerS84carries a particularly high VTE risk.27,28 For the new
thrombopoietin receptor agonists (TRAs) initially an
increased risk had been discussed. Recent studies find
that this is only true when TRAs are given in non-ITP
indications.29,30 In ITP patients with TRAs the risk
seems not to be higher than in ITP patients without
TRAs.31–33 Nevertheless and interestingly, platelet
counts4150,000 (German Fachinformation) or
4200,000 (US food and Drug Administration prescrib-
ing information) should be avoided with TRAs.
ITP AND ATRIAL FIBRILLATION
A Medline search for the terms ‘‘immune thrombo-
cytopenia’’ and ‘‘atrial fibrillation’’ found no publica-
tions on anticoagulation in patients with ITP. Only
one recent article describes the case of a 91-year-old
man with AFib who was started on romiplostim to
raise his platelet counts so he could safely be anti-
coagulated with an oral vitamin K antagonist.34
ITP AND ACUTE MYOCARDIAL INFARCTION
Several case reports describe ITP patients with
AMI.35–39 Thrombocytopenia did not protect against
coronary thrombosis. The authors discuss that ste-
roids or IVIg could have precipitated the acute
events but the patients were also elderly and had
coronary risk factors. AMI has been reported in
conjunction with the use of the new thrombopoietic
agents.31,32 These articles do not comment on post-
AMI anticoagulation.
ITP AND CARDIOVASCULAR SURGERY
In the 1980s, open-heart operations were success-
fully performed together with simultaneous splenec-
tomy.40,41 In the 1990s and 2000s, perioperative
management, such as high-dose immunoglobulins and
platelet transfusions, allowed safe surgical treatment
without splenectomy.42–49 These publications focus on
the perioperative management and do not give recom-
mendations for postoperative anticoagulation.
ITP AND PTCA
Some more recent reports describe successful
percutaneous transluminal coronary angioplasty
(PTCA) in ITP patients. Patients were placed on
acetylsalicylic acid (ASS) and thienopyridines as post-
stenting therapy.50–54 Long-term efficacy and safety
were not reported.
ITP AND STROKE
Few articles describe CVAs or a TIA-like syndrome
in ITP.18,21,55 Because of low platelet counts, anti-
coagulation was not started in one case.56 Otherauthors tried to raise platelet counts to safe levels
before starting anticoagulation.55,57ITP AND VENOUS THROMBOEMBOLISM
ITP patients have a substantial risk of VTE,17
particularly after splenectomy.28,58 VTE has been
reported with the new thrombopoietic agents but
without further details on anticoagulant efficacy and
safety.12,30,59ANTICOAGULATION ASSOCIATED WITH
OTHER TYPES OF THROMBOCYTOPENIA AND
THROMBOPATHY
Thrombotic thrombocytopenic purpura (Mosch-
cowitz syndrome, TTP), heparin-induced thrombo-
cytopenia type II (HIT II), antiphospholipid antibody
syndrome (APS), and disseminated intravascular
coagulation (DIC) are thromboembolic syndromes
with thrombocytopenia and important differential
diagnoses of ITP. The underlying pathophysiologies
differ and so do the therapeutic approaches. VTE is
common in HIT and patients are treated with
therapeutic doses of alternative, non-heparin anti-
coagulants.60 ASS and plasmapheresis are given in
TTP.61 APS patients have a high risk of VTE. When
they are thrombocytopenic at the same time then
management is like maneuvering between a rock
and a hard place because of a high risk of bleeding
and re-thrombosis.62 Heparin has been historically
used as a treatment for DIC with varying outcomes
in different clinical situations.63
As far as congenital platelets disorders are con-
cerned, thrombotic events have been described in
Glanzmann thrombasthenia64–68 and in Bernard–
Soulier syndrome.69–71 Recommendations for ITP
patients cannot be derived from these few cases.PROPHYLAXIS AND TREATMENT
In 1996 the American Society of Hematology pub-
lished its first ITP Guideline to provide guidance to
non-experts of this rare disorder.72 This is still the most
cited article in the field. Several updates and newer
guidelines have been published since then.73–76 None
comments on the management of ITP patients with a
need for anticoagulation. This is due to the scarcity of
clinical data. However, the absence of data should not
justify the absence of opinion.77
Prophylactic anticoagulation is usually offered to
immobilized medical patients or to postoperative
surgical patients. These patients may have a high risk
of thromboembolism (eg, total hip or knee replace-
ment, etc). This risk has to be weighed against the
risk of bleeding in thrombocytopenia. Since patients
do not actually have thromboembolism there is less
ITP patients requiring anticoagulation S85pressure to start anticoagulation right away com-
pared to patients with established thromboembolism.
Anglo-American cancer guidelines recommend
thromboprophylaxis as long as the platelet count
does not fall too50,000/mL.78,79 The Austrian/Ger-
man/Swiss guideline on anticoagulation in cancer
patients is more liberal and allows prophylaxis to a
threshold of 30,000/mL.80 With lower counts,
mechanical prophylaxis (compression stockings,
pneumatic devices) should be considered.
For therapeutic-dose anticoagulation in ITP
patients with severe thrombocytopenia the authors
recommend:– Give corticosteroids and IVIg to raise platelet
counts rapidly to a safe level (ie,430,000–
50,000/mL).– Start TRAs to maintain platelet counts in a
safe range when corticosteroids are tapered
and the effect of IVIg starts to wear off.– Do not give anticoagulation, no matter what
the platelet count, in patients with life-
threatening bleeding or bleeding requiring
transfusion (World Health Organization
[WHO] grade III/IV). Consider a vena cava
filter in DVT patients.– In all other ITP patients (no bleeding,
petechiae, hematomas, stable hemoglobinITP Patient with persistent thrombocy
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standard-dose therapeutic anticoagulation.– With lower counts,o50,000/mL, give half-
standard doses and increase to full doses
when platelets rise to Z50,000/mL.– Further adapt intensity of anticoagulation to
bleeding symptoms and platelet count as
outlined in Figure 1.The treatment algorithm has been derived from
cancer patients with both thromboembolism and a
very high bleeding risk at the same time.81,82 In these
high-risk patients one usually starts with unfractio-
nated heparin (UFH) instead of low-molecular-
weight heparins (LMWH). UFH has a shorter
half-life and can be stopped, monitored, and poten-
tially better reversed immediately when severe
bleeding occurs (at the expense of the necessary
IV line, difficult monitoring and dose adjustments.)
When patients remain without bleeding after 48
hours, one may switch to LMWH.
This algorithm should be regarded as a starting
point for the necessary discussion on how to anti-
coagulate ITP patients with arterial or venous throm-
botic events. Future guidelines will have to address
this issue. Our patients will ask for it.nia
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